336 related articles for article (PubMed ID: 23523692)
1. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Keefe RS; Lieberman JA; Barch DM; Csernansky JG; Goff DC; Gold JM; Green MF; Jarskog LF; Javitt DC; Kimhy D; Kraus MS; McEvoy JP; Mesholam-Gately RI; Seidman LJ; Ball MP; McMahon RP; Kern RS; Robinson J; Marder SR
Biol Psychiatry; 2011 Mar; 69(5):442-9. PubMed ID: 21145041
[TBL] [Abstract][Full Text] [Related]
5. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
6. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
7. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Stauffer VL; Millen BA; Andersen S; Kinon BJ; Lagrandeur L; Lindenmayer JP; Gomez JC
Schizophr Res; 2013 Nov; 150(2-3):434-41. PubMed ID: 24035403
[TBL] [Abstract][Full Text] [Related]
8. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.
Jarskog LF; Lowy MT; Grove RA; Keefe RS; Horrigan JP; Ball MP; Breier A; Buchanan RW; Carter CS; Csernansky JG; Goff DC; Green MF; Kantrowitz JT; Keshavan MS; Laurelle M; Lieberman JA; Marder SR; Maruff P; McMahon RP; Seidman LJ; Peykamian MA
Schizophr Res; 2015 May; 164(1-3):136-42. PubMed ID: 25728831
[TBL] [Abstract][Full Text] [Related]
9. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
[TBL] [Abstract][Full Text] [Related]
10. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder.
Herring WJ; Wilens TE; Adler LA; Baranak C; Liu K; Snavely DB; Lines CR; Michelson D
J Clin Psychiatry; 2012 Jul; 73(7):e891-8. PubMed ID: 22901359
[TBL] [Abstract][Full Text] [Related]
12. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.
Egan M; Yaari R; Liu L; Ryan M; Peng Y; Lines C; Michelson D
Curr Alzheimer Res; 2012 May; 9(4):481-90. PubMed ID: 22272611
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
16. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
17. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
[TBL] [Abstract][Full Text] [Related]
18. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Lindenmayer JP; Khan A
Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
[TBL] [Abstract][Full Text] [Related]
19. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
Haig G; Wang D; Othman AA; Zhao J
Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.
Tuğal O; Yazici KM; Anil Yağcioğlu AE; Göğüş A
Int J Neuropsychopharmacol; 2004 Jun; 7(2):117-23. PubMed ID: 14741060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
